AstraZeneca Agrees to Lower US Medicine Prices
Ticker: AZN · Form: 6-K · Filed: Oct 14, 2025 · CIK: 901832
| Field | Detail |
|---|---|
| Company | Astrazeneca PLC (AZN) |
| Form Type | 6-K |
| Filed Date | Oct 14, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $50b, $50 billion, $80 billion, $20 billion |
| Sentiment | neutral |
Sentiment: neutral
Topics: pricing-agreement, regulatory, us-market
TL;DR
AstraZeneca cuts US drug prices, filing confirms.
AI Summary
AstraZeneca PLC filed a Form 6-K on October 14, 2025, reporting an agreement with the US Government to lower medicine prices. This filing is made pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.
Why It Matters
This agreement could impact AstraZeneca's revenue from the US market and potentially set a precedent for other pharmaceutical companies regarding drug pricing.
Risk Assessment
Risk Level: medium — The agreement to lower prices could negatively affect revenue and profitability, but the exact financial impact is not detailed in this filing.
Key Players & Entities
- AstraZeneca PLC (company) — Registrant
- US Government (company) — Party to agreement
- October 14, 2025 (date) — Filing date
- 1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA United Kingdom (address) — Registrant's address
FAQ
What specific medicines are included in the agreement to lower prices?
The filing does not specify which medicines are included in the agreement to lower prices.
What is the effective date of the agreement to lower medicine prices?
The filing does not state the effective date of the agreement.
What is the expected financial impact of this agreement on AstraZeneca's revenue?
The filing does not provide any financial projections or estimates regarding the impact of the agreement.
Is this agreement part of a broader initiative by the US Government to control drug prices?
The filing mentions an agreement with the US Government but does not provide context on whether it's part of a broader initiative.
Does AstraZeneca file annual reports under Form 20-F?
Yes, AstraZeneca indicates it files annual reports under Form 20-F.
Filing Stats: 973 words · 4 min read · ~3 pages · Grade level 16.8 · Accepted 2025-10-14 06:05:26
Key Financial Figures
- $50b — vation   AstraZeneca to invest $50bn in manufacturing and R&D to support do
- $50 billion — the Company's recently announced  $50 billion investment  in US medicines manufa
- $80 billion — ver the next five years to help deliver $80 billion in Total Revenue by 2030, 50% of which
- $20 billion — 2025, AstraZeneca created approximately $20 billion of overall value to the American econom
Filing Documents
- a9731c.htm (6-K) — 24KB
- 0001654954-25-011688.txt ( ) — 26KB
SIGNATURES
SIGNATURES   Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.     AstraZeneca PLC     Date: 13 October 2025     By: /s/ Matthew Bowden   Name: Matthew Bowden   Title: Company Secretary